Prevalence of human herpes virus 6 (HHV-6) antibodies and vi | 17137
International Research Journals
Reach Us +44 330 818 7254

International Research Journal of Microbiology

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Prevalence of human herpes virus 6 (HHV-6) antibodies and viral DNA in Saudi renal transplant recipients


Obeid E Obeid

Human herpesvirus 6 (HHV-6) is a ß-herpesvirus that is characteristically T-lymphotropic. It is regarded to be a major pathogen in transplant recipients. Very little is known about the prevalence of HHV-6 in Saudi transplant recipients . The aim of the current study was to determine the HHV-6 antibodies (IgM and IgG) and viral DNA in Saudi renal transplant recipients. The study was conducted a tertiary hospital in Eastern Saudi Arabia over a period of 12 months. All kidney transplant recipients who regularly attended the nephrology clinics were included (n=150) (blood donors). Randomly selected control individuals, age and sex matched were recruited to serve as a control group in this study (n=158). Seropostivity for HHV-6 was determined by testing for IgG and IgM antibodies employing HHV-6 EIA and IFA. HHV-6 viral DNA was assessed by real time PCR (Sacace Biotechnologies, Italy). Of the 150 Saudi kidney transplant recipients included in this study, 145 had detectable level of Anti-HHV-6 IgG antibodies (96.7%). Anti-HHV-6 IgG antibodies were detected in 122 out of 158 blood donors (control group; 77.2%). Of the 145 HHV-6 IgG positive transplant recipients, only 4 were found to have detectable levels of anti-HHV-6 IgM antibodies (2.7%). None of the HHV-6 IgG positive blood donors had detectable anti-HHV-6 IgM antibodies. HHV-6 viral DNA was detected by real time PCR in all the 4 HHV-6 IgM-positive individuals (100%). There is a high frequency of detectable HHV-6 in the studied population of renal transplant recipients. Further investigation to monitor HHV-6 primary infection reactivation in graft recipients may prove to be important in improving the outcome for these patients.

Share this article